Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10646	Companies
226446	Keywords
154910	Articles
119856	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 04/16/2024 at 14:30, 2 years 2 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology

Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product
BRIEF

published on 04/09/2024 at 22:20, 2 years 2 months ago

Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial

Jaguar Health Nasdaq Compliance Cancer Therapy Stockholder Meeting Crofelemer Clinical Trial
BRIEF

published on 04/09/2024 at 22:20, 2 years 2 months ago

Jaguar Health annonce une assemblée d’actionnaires réussie et des progrès dans les essais cliniques

Assemblée Générale Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai Clinique Crofelemer
PRESS RELEASE

published on 04/09/2024 at 22:15, 2 years 2 months ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting

Crofelemer Stockholders Meeting Jaguar Health Reverse Split Phase 3 Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 2 months ago

Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon

Crofelemer Jaguar Health Nasdaq Compliance Cancer Therapy OnTarget Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 2 months ago

Jaguar Health obtient une prolongation pour rétablir la conformité au Nasdaq et annonce bientôt les résultats de l'essai OnTarget

Crofelemer Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai OnTarget
PRESS RELEASE

published on 04/08/2024 at 14:30, 2 years 2 months ago

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial

Crofelemer Nasdaq Jaguar Health Cancer Therapy Grace Period
BRIEF

published on 04/02/2024 at 14:35, 2 years 2 months ago

Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International

Pharmaceutical Industry Crofelemer Jaguar Health Massimo Radaelli Commercial Expansion
BRIEF

published on 04/02/2024 at 14:35, 2 years 2 months ago

Jaguar Health, Inc. annonce la nomination d'un vétéran de l'industrie pharmaceutique européenne au poste de président de Jaguar International

Crofelemer Expansion Commerciale Industrie Pharmaceutique Santé Jaguar Massimo Radaelli
PRESS RELEASE

published on 04/02/2024 at 14:30, 2 years 2 months ago

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise

Pharmaceutical Industry Jaguar Health International Expansion Massimo Radaelli Out-license Agreement

Accesswire

Published on 06/26/2026 at 14:05, 37 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 42 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 1 hour 42 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 1 hour 57 minutes ago

Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 01:40, 13 hours 2 minutes ago

UraniumX Announces DTC Eligibility for U.S. Traded Shares

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 14:00, 42 minutes ago

Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 42 minutes ago

Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 10 minutes ago

Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 11 minutes ago

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 12 minutes ago

AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026

Les Echos

Published on 06/26/2026 at 12:16, 2 hours 26 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 7 hours 42 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 7 hours 42 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 19 hours 57 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 20 hours 12 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026

View all LES ECHOS COMFI WIRE